Chemoembolization versus Radiotherapy for Single Hepatocellular Carcinomas of ≤3 cm Unsuitable for Image-Guided Tumor Ablation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Local ablation therapy (LAT) is primarily recommended for solitary inoperable hepatocellular carcinomas (HCCs) of ≤3 cm in diameter. However, only two-thirds of uninodular small HCCs are suitable for LAT, and the second-best treatment option for managing these nodules is unclear. We aimed to compare the therapeutic outcomes of chemoembolization and radiotherapy in small HCCs unsuitable for LAT. Methods: The study included 651 patients from a tertiary referral center who underwent planning sonography for LAT. These patients had 801 solitary HCCs of ≤3 cm in diameter and were treated with LAT, chemoembolization, or radiotherapy. Local tumor progression (LTP)-free survival and overall survival (OS) were measured according to the type of treatment of the index nodule. Results: LAT, chemoembolization, and radiotherapy were used to treat 561, 185, and 55 nodules in 467, 148, and 36 patients, respectively. LTP-free survival was significantly shorter in patients treated with chemoembolization than for those treated with LAT (multivariate hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.61 to 3.47) but not for those treated with radiotherapy (HR, 0.83; 95% CI, 0.38 to 1.83). However, OS was not affected by treatment modality. Matching and weighting analyses confirmed that radiotherapy gave comparable results to chemoembolization in terms of OS despite better LTP-free survival (HR, 2.91; 95% CI, 1.13 to 7.47 and HR, 3.07; 95% CI, 1.11 to 8.48, respectively). Conclusions: Our data suggest that chemoembolization and radiotherapy are equally effective options for single small HCCs found to be unsuitable for LAT after sonographic planning. Better-fit indications for each procedure should be established by specifically designed studies.
Abstract
Background/Aims: Local ablation therapy (LAT) is primarily recommended for solitary inoperable hepatocellular carcinomas (HCCs) of ≤3 cm in diameter. However, only two-thirds of uninodular small HCCs are suitable for LAT, and the second-best treatment option for managing these nodules is unclear. We aimed to compare the therapeutic outcomes of chemoembolization and radiotherapy in small HCCs unsuitable for LAT. Methods: The study included 651 patients from a tertiary referral center who underwent planning sonography for LAT. These patients had 801 solitary HCCs of ≤3 cm in diameter and were treated with LAT, chemoembolization, or radiotherapy. Local tumor progression (LTP)-free survival and overall survival (OS) were measured according to the type of treatment of the index nodule. Results: LAT, chemoembolization, and radiotherapy were used to treat 561, 185, and 55 nodules in 467, 148, and 36 patients, respectively. LTP-free survival was significantly shorter in patients treated with chemoembolization than for those treated with LAT (multivariate hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.61 to 3.47) but not for those treated with radiotherapy (HR, 0.83; 95% CI, 0.38 to 1.83). However, OS was not affected by treatment modality. Matching and weighting analyses confirmed that radiotherapy gave comparable results to chemoembolization in terms of OS despite better LTP-free survival (HR, 2.91; 95% CI, 1.13 to 7.47 and HR, 3.07; 95% CI, 1.11 to 8.48, respectively). Conclusions: Our data suggest that chemoembolization and radiotherapy are equally effective options for single small HCCs found to be unsuitable for LAT after sonographic planning. Better-fit indications for each procedure should be established by specifically designed studies.
참고문헌 (33)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : the 2022update", J Hepatol, 76, pp.681~693 (2022)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
- Korean Liver Cancer Association, "2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma", Gut Liver, 13, pp.227~299 (2019)
- Vogel A, "Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 29(Suppl 4), pp.iv238~iv255 (2018)
- Song KD, "Percutaneous US", MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma : technical feasibility and therapeutic outcomes, 2018, pp.288, 878~886
- Ahn SJ, "Real-time US-CT", MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma, 2017, pp.66, 347~354
- Kim JE, "Outcomes of patients with hepatocellular carcinoma referred for percutaneous radiofrequency ablation at a tertiary center : analysis focused on the feasibility with the use of ultrasonography guidance", Eur J Radiol, 79, pp.e80~e84 (2011)
- Rhim H, "Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas", AJR Am J Roentgenol, 190, pp.1324~1330 (2008)
- Burrel M, "Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation(TACE)using drug eluting beads : implications for clinical practice and trial design", J Hepatol, 56, pp.1330~1335 (2012)
- Kim JW, "Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller", Am J Gastroenterol, 109, pp.1234~1240 (2014)
- Yun BY, "Prognosis of early-stage hepatocellular carcinoma : comparison between trans-arterial chemoembolization and radiofrequency ablation", Cancers(Basel), 12, pp.2527~ (2020)
- Wang Y, "Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma : a meta-analysis", Hepatol Res, 46, pp.58~71 (2016)
- Yoon SM, "Stereotactic body radiation therapy for small(≤5 cm)hepatocellular carcinoma not amenable to curative treatment : results of a single-arm, phase II clinical trial", Clin Mol Hepatol, 26, pp.506~515 (2020)
- Wahl DR, "Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma", J Clin Oncol, 34, pp.452~459 (2016)
- Kim N, "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma", J Hepatol, 73, pp.121~129 (2020)
- Kudo M, "Hepatocellular carcinoma : therapeutic guidelines and medical treatment", Liver Cancer, 6, pp.16~26 (2016)
- Chu HH, "Surgical resection versus radiofrequency ablation very early-stage HCC(≤2 cm single HCC) : a propensity score analysis", Liver Int, 39, pp.2397~2407 (2019)
- Gwon D 2nd, "Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava : incidence, characteristics, and risk factors and clinical efficacy of TACE", Radiology, 254, pp.617~626 (2010)
- Park J, "Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma", BMC Cancer, 18, pp.1040~ (2018)
- Cho SM, "Initial transarterial chemoembolization(TACE)using HepaSpheres 20-40 μm and subsequent lipiodol TACE in patients with hepatocellular carcinoma >5 cm", Life(Basel), 11, pp.358~ (2021)
- Shim JH, "Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models", Radiology, 262, pp.708~718 (2012)
- Rhim H, "Radiofrequency ablation of hepatocellular carcinoma : pros and cons", Gut Liver, 4(Suppl 1), pp.S113~S118 (2010)
- Kang TW, "Long-term therapeutic outcomes of radiofrequency ablation for subcapsular versus nonsubcapsular hepatocellular carcinoma : a propensity score matched study", Radiology, 280, pp.300~312 (2016)
- Hsu CY, "Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria : a propensity score analysis", Liver Transpl, 17, pp.556~566 (2011)
- Miyayama S, "Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma", Hepatol Res, 39, pp.374~381 (2009)
- Kim TH, "Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma : a randomized phase III trial", J Hepatol, 74, pp.603~612 (2021)
- Mohamed M, "Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma", Adv Radiat Oncol, 1, pp.35~42 (2015)
- Su TS, "Stereotactic body radiation therapy vs. transarterial chemoembolization in inoperable Barcelona Clinic Liver Cancer stage a hepatocellular carcinoma : a retrospective, propensity-matched analysis", Front Oncol, 10, pp.347~ (2020)
- Jung J, "Stereotactic body radiation therapy for hepatocellular carcinoma", J Liver Cancer, 18, pp.94~102 (2018)
- Sieghart W, "Transarterial chemoembolization : modalities, indication, and patient selection", J Hepatol, 62, pp.1187~1195 (2015)
- Kawaoka T, "Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma", J Vasc Interv Radiol, 21, pp.1219~1225 (2010)
- Lee IJ, "Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients", Ther Adv Med Oncol, 11, pp.1758835919866072~ (2019)